Corcept is a commercial-stage pharmaceutical company that discovers and develops medications modulating cortisol's effects to treat endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym, an FDA-approved treatment for hypercortisolism (Cushing's syndrome), and maintains a proprietary pipeline of selective cortisol modulators designed to eliminate side effects associated with existing therapies by targeting the glucocorticoid receptor without affecting the progesterone receptor. Lead pipeline candidates including relacorilant, nenocorilant, miricorilant, and dazucorilant are in clinical development across indications spanning resistant hypertension, difficult-to-control diabetes, ovarian cancer, endometrial cancer, pancreatic cancer, metabolic dysfunction-associated steatohepatitis, and amyotrophic lateral sclerosis. Corcept generates revenue from Korlym sales through direct specialty pharmacy distribution and patient support programs while investing substantially in research and development to advance its proprietary pipeline candidates toward regulatory approval.